603351 Nanjing Well Pharmaceutical Group
- 23.92
- -0.27-1.12%
Nanjing Well Pharmaceutical Group News
Well Pharmaceutical (603351): Lower raw material prices, depreciation and equity incentive expenses affect profits
Will Pharmaceutical (603351): a substantial increase in income, rising costs, depreciation and equity incentive fees affect profits
Will Pharmaceutical (603351): pilot production of squalene, an important vaccine adjuvant, is registered in the fundraising project.
Well Pharmaceutical (603351): Injectable drugs supplement vaccine excipients are beginning to contribute to performance
Will Pharmaceutical (603351): the construction of the fund-raising project is drawing to a close. 21-year performance is expected to usher in an inflection point.
Well Pharmaceutical (603351): Potential Beneficiaries of Consistency Evaluation of Injectable Drug Supplements
Well Pharmaceutical (603351): Excellent supplier of pharmaceutical excipients and lubricating base oils in China
No Data